|
|
|
GTCbio, Philadelphia, PA
Mar 5-7, 2008
Day 1, Wednesday, March 5, 2008 1:30 Registration 2:25 Welcome and Opening Remarks Session I - New Technologies in Anti-Infectives - Part I 2:30 Marc Mittelman Vice President, Research & Development, Cernofina 3:00 Dawn Eringis Vice President, Business Development, PolyMedix 3:30 Mark Alfenito Executive Vice President, Corporate Development, Kalobios 4:00 CB Rao Deputy Managing Director, Orgenus Pharma, Inc. 4:30 Rodger Novak Chief Operating Officer, Nabriva Therapeutics 5:00 Fludase: Reshaping the Management of Influenza-Like Illness; A Novel Mechanism Helps More Doctors to do the Right Thing David Wurtman, Vice President, Corporate Development, NexBio, Inc. 5:30 Poster Session & Networking Reception Day 2, Thursday, March 6, 2008 7:00 Registration & Breakfast 7:55 Welcome and Opening Remarks [KEYNOTE PRESENTATION] 8:00 A Vaccine Renaissance: New Vaccines for the World John W. Shiver, Vice President, Worldwide Basic Research Franchise Head, Vaccines, Merck and Co., Inc. Session II - Current Models of R&D Collaboration - Part I 8:45 The Novartis / Human Genome Sciences Albuferon Alliance - Key Success Factors in Driving Successful Biotech / Big Pharma Alliances Mark Coflin, Global Exec. Dir., IDTI Alliance Mgmt, Novartis Pharmaceuticals Corporation Margery B. Fischbein, Vice President, Business Development & Strategic Planning, Human Genome Sciences 9:30 Replenishing the GSK Infectious Disease R&D Pipeline Using Innovative Deals Structures with Strategic Collaborators Damien McDevitt Ph.D., Director, Business Development, Infectious Diseases CEDD/CEEDD, & World Wide Business Development, GlaxoSmithKline 10:00 Networking & Refreshment Break 10:30 Biota-Boehringer Ingelheim: Making the Right Deal: It’s Not Just About the Money James Chafouleas, Director, Global Licensing – Virology, Boehringer Ingelheim Leigh Farrell, Vice President, Business Development, Biota 11:15 Opportunitistic Partnerships in Infectious Diseases - What Big Pharma are Looking For Douglas Pon, Assistant Vice President, Vaccine Licensing Global Business Development, Wyeth [PANEL DISCUSSION] 11:45 Developing Partnerships with Big Pharma 12:30 Lunch Session III - New Pathogen Challenges 1:30 Overview of the Antibacterial Pipeline and Future Areas of Opportunity, 2008 Danielle Drayton, Ph.D., Senior Analyst, Decision Resources 2:00 Multi-Resistant Pseudomonas and Acinetobacter - Challenges and Perspectives Malcolm Page, Head, Discovery Biology, Basilea Pharmaceuticals 2:30 Genetic Determinants of Tetracycline Resistance and their Occurrence in Escherichia Coli Isolates from the Pivotal Tigecycline Phase 3 Clinical Trials Hal Jones, Ph.D., Principal Research Scientist II, Wyeth 3:00 Networking and Refreshment Break 3:30 Clostridum Difficile Infection: A Slumbering Giant Awakened? Glenn Tillotson, Ph.D., Executive Director of Scientific Affairs, Replidyne, Inc. 4:00 Your ‘Plan B’ When All Else Fails? Another Alternative for Your Anti-Infective Compounds Paul A. Stewart, Manager, Global Business Development, Elanco Animal Health Division, Eli Lilly and Company [PANEL DISCUSSION] 4:30 Investment Opportunities in the Anti-Infectives Space Panelists: Eric C. Meltzer, Managing Director, Curtis Financial Group (Moderator) Lisa Gray, Managing Partner, Phoenix IP Ventures Jennifer H. Hartt, Director of Investments, Life Sciences, Investment Group, Ben Franklin Technology Partners Gary Patou, Executive Partner, MPM Capital 5:15 Poster Session & Networking Top of the page Day 3, Friday, March 7, 2008 7:30 Continental Breakfast 7:55 Chairperson’s Review of Day One Session IV - Current Models of R&D Collaboration - Part II 8:00 Collaborating with Public-Private Partnerships: The Global Alliance for TB Drug Development Gerald Siuta, Head of Business Development, Global Alliance for TB Drug Development 8:30 R&D Externalization Strategies Jacques Dumas, Associate Director, Infection Chemistry, Astra Zeneca R&D Session V - Future of Infectious Disease Therapeutics 9:00 Making the Golden Goose - How to Obtain and Manage Intellectual Property that Maximizing the Value of Your Deal. Mike Fuller, Knobbe Martens Olson & Bear 9:30 Regulatory Approval of Antibacterial Drugs: New Science or New Agenda? Roger M. Echols, M.D., Chief Medical Officer, Replidyne, Inc. 10:00 Networking and Refreshment Break 10:30 Positioning Antibacterials within the Hospital and Community Markets amid Regulatory Changes and Continuing Uncertainty Dennis Molnar, M.B.A., Vice President, Corporate Development, Paratek Pharmaceuticals 11:00 Combination Therapy / Dual Mechanism Agents Michael Dudley, Vice President of Drug Development, Mpex Pharmaceuticals [PANEL DISCUSSION] 11:30 Future of Infectious Disease Therapeutics (cont..) 12:15 Luncheon Session VI - New Technologies in Anti-Infectives - Part II 1:15 Targeted Molecular Immunogens (Tarmogens®)/ Harnessing Cellular Immunity for the Treatment of Infectious Disease David Apelian, Chief Medical Officer, Globeimmune 1:45 Oritavancin, a Potent Lipo-Glycopeptide with Unusual Pharmacokinetic Properties that may Allow Single or Infrequent Dosing Schedules Thomas Parr, Chief Scientific Officer, Targanta 2:15 Hepatitis B Vaccine: Hepislav Michael S. Ostrach, Chief Business Officer, Dynavax Technologies Corporation 2:45 Kim Morse, Acambis 3:15 Conference Concludes
|
|
|
|
|
|
Organized by:
|
|
Nina Tran |
|
Invited Speakers:
|
|
Visit our web to see invited speakers!
|
|
|
|
|
|
Deadline for Abstracts:
|
|
February, 2008
|
|
|
|
|
|
Registration:
|
|
Register 2, the 3rd goes FREE - Register Now!
20% off if you register by January 5, 2008.
|
|
E-mail:
|
|
nina.tran@gtcbio.com
|
|
|
|
|
|
|
|